Announcement PDF ASX Announcement 21 May 2025 MetaPanel Pathogen Study Delivers Breakthrough Results Results at a glance: • • Analysis of 889 MetaPanelTM tests from a patient cohort characterised by long-term gastrointestinal symptoms shows that: o 20.0% of patients test positive for a pathogen that can cause gastrointestinal infection o 78.4% of the pathogens detected by MetaPanel are often missed by routine pathology tests o Additionally, 58.3% of tests reveal abnormal microbiome results, supporting referral to a MetaXploreTM test for further investigation 100% of patients treated for a pathogen detected by MetaPanel experienced complete symptom resolution in an independent study. Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces compelling new data demonstrating the ability of its MetaPanel™ test to identify clinically significant pathogens that are often missed by standard diagnostic approaches, guide treatment, and achieve symptom resolution. MetaPanelTM is an advanced gastrointestinal pathogen detection panel that screens for 115 pathogens and virulence factors, including bacteria, viruses and parasites. It is designed to address the limitations of conventional diagnostics, which only detect a limited range of clinically relevant pathogens, and often fail to identify the underlying cause of persistent symptoms. To support clinicians in providing effective treatment, each MetaPanelTM result is reviewed by an expert pathologist who provides interpretation and treatment recommendations, including antibiotic selection guided by detected pathogens, resistance genes, and commensal flora. An in-depth analysis of billing and claims data for relevant gastrointestinal symptoms has estimated an addressable population of 82.2 million patients across US, Germany, Italy, Spain, France, United Kingdom and Australia. Current routine gastrointestinal testing approaches leave approximately 50% of patients with chronic gastrointestinal (GI) symptoms without symptom resolution¹. Microba’s findings in this study suggest that a substantial proportion of these unresolved cases can be attributable to undetected intestinal infections, and that therapy guided by MetaPanel test results can deliver symptom resolution. By revealing these hidden causes of chronic gastrointestinal (GI) symptoms, MetaPanelTM offers a novel diagnostic and therapeutic pathway for these patients. MetaPanel™ Reveals Pathogens in 20% of Patients An analysis of 889 MetaPanelTM reports from a patient cohort characterised by long-term GI symptoms, who have not resolved their condition through routine testing, found that: • 20.0% of samples (178/889) tested positive for a pathogen, including 2.4% which were positive for multiple pathogens. . JOIN MICROBA’S INTERACTIVE INVESTOR HUB Visit ir.microba.com/welcome for Microba’s interactive Investor Hub Microba Life Sciences Ltd ABN 82 617 096 652 | Level 10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 ASX Announcement 21 May 2025 • The majority of clinically relevant positive results — approximately 78% — that are often missed by routine tests used in Australia, including traditional PCR panels and microscopy culture sensitivity (MCS/OCS). • MetaPanel's broader target set of 115 pathogens and virulence factors allows for the detection of the long tail of clinically significant pathogens frequently missed by routine testing. Here we show that collectively these pathogens are found in a substantial number of patients with chronic GI symptoms. • An additional 58.3% of tests (518/889) showed abnormal microbiome results, which may be targeted through nutritional and/or lifestyle interventions, and support reflex or referral to a MetaXplore™ test for further investigation. • Case reports show that targeted treatment from the expert pathologist recommendations in the report leads to complete symptom resolution in most patients, including cases with several years of chronic gastrointestinal symptoms. These results demonstrate that MetaPanelTM is a powerful new tool for clinicians managing complex gastrointestinal cases. The ability to detect pathogens missed by routine tests enables clinicians to uncover the hidden infectious causes of persistent GI symptoms and deliver targeted, effective treatment. This study is ongoing, supports the integration of MetaPanelTM testing into standard care protocols, and is being prepared for publication in a peer-reviewed journal. Associate Professor Michael Wehrhahn, Director of Molecular Biology/Infectious Serology at Douglass Hanly Moir Pathology, who is leading this study, commented: “These findings are an important advancement in how we diagnose and treat chronic gastrointestinal symptoms. The ability of MetaPanel to detect pathogens that evade routine testing — and achieve complete symptom resolution in many treated cases — highlights its potential to transform patient outcomes.” Clinical Outcomes: 100% Resolution in Treated Patients In an independent study of 42 patients with chronic diarrhoea carried out with The Colonoscopy Clinic in Queensland, Australia, 19% of patients (8/42) tested positive for a pathogen with MetaPanelTM. All cases (100%) who were treated using the expert pathologist report recommendation for the detected pathogen, experienced complete symptom resolution. These promising early results support the inclusion of MetaPanelTM in routine testing protocols for chronic gastrointestinal symptoms. A/Prof Lutz Krause, Chief Scientific Officer at Microba, commented: “These encouraging results demonstrate the ability of MetaPanel to detect clinically significant pathogens that are missed by standard pathology tests. The symptom resolution observed in all treated patients underscores its potential to transform outcomes for patients with chronic GI conditions. This data exemplifies the strength of our partnership with the Colonoscopy Clinic in demonstrating the clinical utility of Microba’s tests and advancing precision gastroenterology.” Setting a New Diagnostic Standard in Gastroenterology MetaPanel™ provides a paradigm shift to pathogen detection, addressing critical gaps in current diagnostic practice: 1. Detection of pathogens missed by routine tests across a broad range of GI diseases 2. Assessment of antimicrobial resistance genes to guide more effective treatment 3. Interpretation and treatment guidance from expert pathologists, allowing clinicians to act with greater confidence Additionally, MetaPanelTM includes microbiome markers which can guide appropriate reflex or referral to MetaXplore™ testing where pathogen-negative results require further investigation. 1 Gordon, J., Miller, G., & Valenti, L. (2015). The management of unresolved gastrointestinal symptoms in Australian general practice. Australian Family Physician, 44(9), 621-623 . JOIN MICROBA’S INTERACTIVE INVESTOR HUB Visit ir.microba.com/welcome for Microba’s interactive Investor Hub Microba Life Sciences Ltd ABN 82 617 096 652 | Level 10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 ASX Announcement 21 May 2025 This announcement has been authorised for release by the Chair and Chief Executive Officer. For further information, please contact: Dr Luke Reid Chief Executive Officer luke.reid@microba.com https://ir.microba.com/welcome About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com View this announcement on our Investor Hub: https://ir.microba.com/link/Dex4me . JOIN MICROBA’S INTERACTIVE INVESTOR HUB Visit ir.microba.com/welcome for Microba’s interactive Investor Hub Microba Life Sciences Ltd ABN 82 617 096 652 | Level 10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621